Pricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Income before tax

RIBOMIC Inc.【JP:4591】

Market cap
¥4.4B
P/E ratio
-3.8x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndIncome before tax (Million JPY)YoY (%)
Mar 31, 2025-1,015+3.26%
Mar 31, 2024-983-40.41%
Mar 31, 2023-1,649+0.84%
Mar 31, 2022-1,636+38.02%
Mar 31, 2021-1,185+38.79%
Mar 31, 2020-854+2.23%
Mar 31, 2019-835+11.12%
Mar 31, 2018-752+14.08%
Mar 31, 2017-659+104.55%
Mar 31, 2016-322-2541.10%
Mar 31, 201513-106.26%
Mar 31, 2014-211-23.40%
Mar 31, 2013-275-11.89%
Mar 31, 2012-312

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)